PDF) Kawasaki Disease
PIMS-TS diagnostic and therapeutic algorithm. | Download Scientific Diagram
Erratum zu: Handlungsempfehlung nach der Leitlinie „Vaskulitiden – Kawasaki-Syndrom“ | springermedizin.de
COVID-19: Berichte über Kawasaki-Syndrom bei Kindern
PDF) Acute phase of Kawasaki disease: a review of national guideline recommendations
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association | Circulation
Erste Leitlinie zum Kawasaki-Syndrom vorgestellt | springermedizin.de
Frontiers | Kawasaki Disease
Halsschmerzen
Leitlinien-Update zu Thoraxschmerzen, Synkope, Kawasaki-Syndrom - coliquio
Frontiers | Kawasaki Disease
Acute phase of Kawasaki disease: a review of national guideline recommendations. - Abstract - Europe PMC
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association | Circulation
S2k‐Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes – Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen - Worm - 2021 - JDDG: Journal der Deutschen Dermatologischen Gesellschaft - Wiley Online Library
Leitlinie Kawasaki Syndrom (S2k Leitlinie)
Coronary artery lesion in Kawasaki disease during follow-up. Extensive... | Download Scientific Diagram
Frontiers | Kawasaki Disease
Frontiers | Kawasaki Disease
Leitlinie Kawasaki Syndrom (S2k Leitlinie)
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association | Circulation
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association | Circulation
Frontiers | Kawasaki Disease
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association | Circulation
Leitlinie Kawasaki Syndrom (S2k Leitlinie)
Leitlinie S1 für das Management postviraler Zustände am Beispiel Post-COVID-19 | Wiener klinische Wochenschrift
